Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ganaplacide - Imidazolopiperazines derivative Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03167242 (CKAF156A2202) Malaria Phase 2 PCR-corrected adequate clinical and parasitological response (ACPR) KAF156 and LUM-SDF (different combinations) Coartem Adults and children with uncomplicated Plasmodium falciparum malaria H2-2021 (actual) No new publications NCT04546633 KALUMI (CKAF156A2203) Malaria, uncomplicated Phase 2 PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 12 to < 18 years old with malaria caused by P. falciparum 2022 TBD 135 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation